{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T17:05:04Z","timestamp":1788109504188,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The immunogenicity and safety of a booster dose of tetanus toxoid-conjugate quadrivalent meningococcal vaccine (MenACYW-TT), alone or co-administered with MenB vaccine, were assessed in healthy 13\u201325-year olds who received MenACYW-TT or a CRM-conjugate vaccine (MCV4-CRM) 3\u20136 years earlier.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This phase IIIb open-label trial (NCT04084769) evaluated MenACYW-TT-primed participants, randomized to receive MenACYW-TT alone or with a MenB vaccine, and MCV4-CRM-primed participants who received MenACYW-TT alone. Functional antibodies against serogroups A, C, W and Y were measured using human complement serum bactericidal antibody assay (hSBA). The primary endpoint was vaccine seroresponse (post-vaccination titers \u22651:16 if pre-vaccination titers &lt;1:8; or a \u22654-fold increase if pre-vaccination titers \u22651:8) 30 days post booster. Safety was evaluated throughout the study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The persistence of the immune response following primary vaccination with MenACYW-TT was demonstrated. Seroresponse after MenACYW-TT booster was high regardless of priming vaccine (serogroup A: 94.8% vs 93.2%; C: 97.1% vs 98.9%; W: 97.7% vs 98.9%; and Y; 98.9% vs 100% for MenACWY-TT-primed and MCV4-CRM-primed groups, respectively). Co-administration with MenB vaccines did not affect MenACWY-TT immunogenicity. No vaccine-related serious adverse events were reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>MenACYW-TT booster induced robust immunogenicity against all serogroups, regardless of the primary vaccine received, and had an acceptable safety profile.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Impact<\/jats:title>\n                <jats:p><jats:list list-type=\"bullet\">\n                  <jats:list-item>\n                    <jats:p>A booster dose of MenACYW-TT induces robust immune responses in children and adolescents primed with MenACYW-TT or another MCV4 (MCV4-DT or MCV4-CRM), respectively.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>Here, we demonstrate that MenACYW-TT booster 3\u20136 years after primary vaccination induced robust immunogenicity against all serogroups, regardless of the priming vaccine (MenACWY-TT or MCV4-CRM), and was well tolerated.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>Persistence of the immune response following previous primary vaccination with MenACYW-TT was demonstrated.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>MenACYW-TT booster with MenB vaccine co-administration did not affect MenACWY-TT immunogenicity and was well tolerated.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>These findings will facilitate the provision of broader protection against IMD particularly in higher-risk groups such as adolescents.<\/jats:p>\n                  <\/jats:list-item>\n                <\/jats:list><\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41390-023-02478-5","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T13:03:05Z","timestamp":1678453385000},"page":"1035-1043","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study"],"prefix":"10.1038","volume":"94","author":[{"given":"Betzana","family":"Zambrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Deseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Julien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford","family":"Seyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Brabec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germ\u00e1n","family":"\u00c1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Hagenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Von Barbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kucku","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Jordanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep Singh","family":"Dhingra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"2478_CR1","unstructured":"European Centre for Disease Prevention and Control (ECDC). Factsheet about meningococcal disease. https:\/\/www.ecdc.europa.eu\/en\/meningococcal-disease\/factsheet, (accessed October 2021)."},{"key":"2478_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/322587","volume":"33","author":"LJ Erickson","year":"2001","unstructured":"Erickson, L. J., De Wals, P., McMahon, J. & Heim, S. Complications of meningococcal disease in college students. Clin. Infect. Dis. 33, 737\u2013739 (2001).","journal-title":"Clin. Infect. Dis."},{"key":"2478_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7954-11-17","volume":"11","author":"RZ Jafri","year":"2013","unstructured":"Jafri, R. Z. et al. Global epidemiology of invasive meningococcal disease. Popul. Health Metr. 11, 17 (2013).","journal-title":"Popul. Health Metr."},{"key":"2478_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","volume":"10","author":"H Christensen","year":"2010","unstructured":"Christensen, H., May, M., Bowen, L., Hickman, M. & Trotter, C. L. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 10, 853\u2013861 (2010).","journal-title":"Lancet Infect. Dis."},{"key":"2478_CR5","first-page":"E121","volume":"56","author":"S Bosis","year":"2015","unstructured":"Bosis, S., Mayer, A. & Esposito, S. Meningococcal disease in childhood: epidemiology, clinical features and prevention. J. Prev. Med. Hyg. 56, E121\u2013E124 (2015).","journal-title":"J. Prev. Med. Hyg."},{"key":"2478_CR6","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","volume":"35","author":"R Whittaker","year":"2017","unstructured":"Whittaker, R. et al. The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004-2014. Vaccine 35, 2034\u20132041 (2017).","journal-title":"Vaccine"},{"key":"2478_CR7","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/21645515.2018.1532248","volume":"15","author":"R Booy","year":"2019","unstructured":"Booy, R., Gentile, A., Nissen, M., Whelan, J. & Abitbol, V. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum. Vaccin. Immunother. 15, 470\u2013480 (2019).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2478_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jamapediatrics.2020.1990","volume":"174","author":"S Mbaeyi","year":"2020","unstructured":"Mbaeyi, S. et al. Incidence of meningococcal disease before and after implementation of quadrivalent meningococcal conjugate vaccine in the United States. JAMA Pediatr. 174, 843\u2013851 (2020).","journal-title":"JAMA Pediatr."},{"key":"2478_CR9","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/cid\/ciu601","volume":"59","author":"MW Bijlsma","year":"2014","unstructured":"Bijlsma, M. W., Brouwer, M. C., Spanjaard, L., van de Beek, D. & van der Ende, A. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination. Clin. Infect. Dis. 59, 1216\u20131221 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"2478_CR10","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3201\/eid2307.170236","volume":"23","author":"H Campbell","year":"2017","unstructured":"Campbell, H. et al. Emergency meningococcal ACWY vaccination program for teenagers to control group W meningococcal disease, England, 2015\u20132016. Emerg. Infect. Dis. 23, 1184\u20131187 (2017).","journal-title":"Emerg. Infect. Dis."},{"key":"2478_CR11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s40265-013-0079-2","volume":"73","author":"AC Cohn","year":"2013","unstructured":"Cohn, A. C. & Harrison, L. H. Meningococcal vaccines: current issues and future strategies. Drugs 73, 1147\u20131155 (2013).","journal-title":"Drugs"},{"key":"2478_CR12","doi-asserted-by":"publisher","first-page":"e1099","DOI":"10.1093\/cid\/ciaa1774","volume":"73","author":"DLH Koelman","year":"2021","unstructured":"Koelman, D. L. H. et al. Changing epidemiology of bacterial meningitis since introduction of conjugate vaccines: 3 decades of national meningitis surveillance in The Netherlands. Clin. Infect. Dis. 73, e1099\u2013e1107 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"2478_CR13","first-page":"1","volume":"62","author":"AC Cohn","year":"2013","unstructured":"Cohn, A. C. et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 62, 1\u201328 (2013).","journal-title":"MMWR Recomm. Rep."},{"key":"2478_CR14","unstructured":"European Center For Disease Prevention and Control (ECDC). Meningococcal disease: recommended vaccinations. https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1(accessed December 2021)."},{"key":"2478_CR15","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3390\/microorganisms8101521","volume":"8","author":"M Pizza","year":"2020","unstructured":"Pizza, M., Bekkat-Berkani, R. & Rappuoli, R. Vaccines against meningococcal diseases. Microorganisms 8, 1521 (2020).","journal-title":"Microorganisms"},{"key":"2478_CR16","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/14760584.2018.1521280","volume":"17","author":"P Keshavan","year":"2018","unstructured":"Keshavan, P., Pellegrini, M., Vadivelu-Pechai, K. & Nissen, M. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine. Expert Rev. Vaccines 17, 865\u2013880 (2018).","journal-title":"Expert Rev. Vaccines"},{"key":"2478_CR17","unstructured":"Australian Government Department of Health. Meningococcal immunisation service. https:\/\/www.health.gov.au\/health-topics\/immunisation\/immunisation-services\/meningococcal-immunisation-service-0 (accessed December 2021)."},{"key":"2478_CR18","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1097\/INF.0b013e31823e1e34","volume":"31","author":"J McVernon","year":"2012","unstructured":"McVernon, J. et al. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers. Pediatr. Infect. Dis. J. 31, e15\u2013e23 (2012).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"2478_CR19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/INF.0000000000002832","volume":"39","author":"CI Baccarini","year":"2020","unstructured":"Baccarini, C. I. et al. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine in healthy meningococcal-na\u00efve children 2-9 years of age: a phase III, randomized study. Pediatr. Infect. Dis. J. 39, 955\u2013960 (2020).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"2478_CR20","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1016\/j.vaccine.2020.06.013","volume":"38","author":"MS Dhingra","year":"2020","unstructured":"Dhingra, M. S. et al. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study. Vaccine 38, 5194\u20135201 (2020).","journal-title":"Vaccine"},{"key":"2478_CR21","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/21645515.2020.1733868","volume":"16","author":"J Kirstein","year":"2020","unstructured":"Kirstein, J., Pina, M., Pan, J., Jordanov, E. & Dhingra, M. S. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study. Hum. Vaccin. Immunother. 16, 1299\u20131305 (2020).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2478_CR22","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.vaccine.2022.01.050","volume":"40","author":"MJ Cornish","year":"2022","unstructured":"Cornish, M. J. et al. Safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in infants and toddlers: a Phase II study. Vaccine 40, 1421\u20131438 (2022).","journal-title":"Vaccine"},{"key":"2478_CR23","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1080\/21645515.2020.1733867","volume":"16","author":"G \u00c1\u00f1ez","year":"2020","unstructured":"\u00c1\u00f1ez, G. et al. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study. Hum. Vaccin. Immunother. 16, 1292\u20131298 (2020).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2478_CR24","doi-asserted-by":"crossref","unstructured":"Piazza, F. M. et al. Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: a Phase III, open-label, multi-center study. Hum. Vaccin. Immunother. 18, 1\u201310 (2022).","DOI":"10.1080\/21645515.2021.1902701"},{"key":"2478_CR25","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1016\/j.vaccine.2020.03.017","volume":"38","author":"L-J Chang","year":"2020","unstructured":"Chang, L.-J. et al. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine 38, 3560\u20133569 (2020).","journal-title":"Vaccine"},{"key":"2478_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","volume":"4","author":"SE Maslanka","year":"1997","unstructured":"Maslanka, S. E. et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin. Diagn. Lab Immunol. 4, 156\u2013167 (1997).","journal-title":"Clin. Diagn. Lab Immunol."},{"key":"2478_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","volume":"379","author":"ME Santolaya","year":"2012","unstructured":"Santolaya, M. E. et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study. Lancet (Lond., Engl.) 379, 617\u2013624 (2012).","journal-title":"Lancet (Lond., Engl.)"},{"key":"2478_CR28","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1080\/21645515.2018.1425659","volume":"14","author":"NC Chiu","year":"2018","unstructured":"Chiu, N. C. et al. Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: a phase 3, open-label, randomized study. Hum. Vaccin. Immunother. 14, 1075\u20131083 (2018).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2478_CR29","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","volume":"381","author":"T Vesikari","year":"2013","unstructured":"Vesikari, T. et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet (Lond., Engl.) 381, 825\u2013835 (2013).","journal-title":"Lancet (Lond., Engl.)"},{"key":"2478_CR30","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa1614474","volume":"377","author":"L Ostergaard","year":"2017","unstructured":"Ostergaard, L. et al. A bivalent meningococcal B vaccine in adolescents and young adults. N. Engl. J. Med. 377, 2349\u20132362 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2478_CR31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/jpids\/piv039","volume":"5","author":"T Vesikari","year":"2015","unstructured":"Vesikari, T. et al. Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J. Pediatr. Infect. Dis. Soc. 5, 152\u2013160 (2015).","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"2478_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40265-018-0869-7","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley, M. & Taha, M.-K. MenB-FHbp meningococcal group B vaccine (Trumenba\u00ae): a review in active immunization in individuals aged \u2265 10 years. Drugs 78, 257\u2013268 (2018).","journal-title":"Drugs"}],"updated-by":[{"DOI":"10.1038\/s41390-023-02835-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000}}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-023-02478-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-023-02478-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-023-02478-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T04:04:43Z","timestamp":1697688283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-023-02478-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2478"],"URL":"https:\/\/doi.org\/10.1038\/s41390-023-02478-5","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41390-023-02835-4","asserted-by":"object"}]},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,10]]},"assertion":[{"value":"20 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41390-023-02835-4","URL":"https:\/\/doi.org\/10.1038\/s41390-023-02835-4","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.Z., J.S., J.Pa., A.H., D.V.B., K.V., E.J. and M.S.D. are employees of Sanofi and may hold stocks\/shares. C.D., K.J. and J.Pe. received funding from Sanofi to support work for the trial. B.B., R.H., M.S., C.Se., C.Sp.\u00a0and M.A. have no conflicts of interest to declare. G.\u00c1. was an employee of Sanofi at the time this study was conducted.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Participants aged \u226513 to <18 years of age signed an assent form and their parent or guardian signed and dated the informed consent form (ICF) before any procedure or treatment associated with the trial performed. Those \u226518 years of age signed and dated the ICF themselves.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}